Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Remer Consultores Assessoria Empresarial Ltda has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct art unit and is being reviewed by 1 distinct examiner. The portfolio's current activity is highly concentrated in this specific technical field. The company's current patent strategy is entirely dependent on the resolution of this single matter within the Biotechnology & Pharmaceuticals technology area.
The busiest examiner for the company is KATAKAM, SUDHAKAR, who is currently handling 1 pending office action. This represents the only active prosecution matter for the entity. Efficiently addressing the 1 pending office action with this specific examiner is the primary task for the company's current patent strategy. The outcome of this 1 pending office action is the current focus of the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KATAKAM, SUDHAKAR | 1 | 74.8% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260270 | USE OF COMPOUND, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IMMUNE OR METABOLIC DISORDERS, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ILLNESSES CAUSED BY OR ASSOCIATED WITH VIRUSES | KATAKAM, SUDHAKAR | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260270 | USE OF COMPOUND, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IMMUNE OR METABOLIC DISORDERS, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ILLNESSES CAUSED BY OR ASSOCIATED WITH VIRUSES | KATAKAM, SUDHAKAR | 1658 | §103 | Final Rejection | — | Pending | Jul 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRemer Consultores Assessoria Empresarial Ltda has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Sudhakar Katakam has the most, with 1 of Remer Consultores Assessoria Empresarial Ltda's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.